Covered recipient · General Payments record
VENKATESH K NADAR
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$9,694.81
202 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $5,680.72 | 190 |
| Travel and Lodging | $4,014.09 | 12 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
VENKATESH K NADAR
NPI 1154383826 · CMS profile ID 187941
Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
CAMP HILL, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1154383826?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- VENKATESH K NADAR, NPI 1154383826, CMS profile ID 187941. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154383826?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). VENKATESH K NADAR, NPI 1154383826, CMS profile ID 187941. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154383826?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- VENKATESH K NADAR, NPI 1154383826, CMS profile ID 187941, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1154383826?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
202 matching records · $9,694.81 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 202.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. | $124.99 | 08/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1081702743 | CMS |
| Tactile Systems Technology Inc | $13.87 | 08/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1082375667 | CMS |
| Novartis Pharmaceuticals Corporation | $18.78 | 08/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086961254 | CMS |
| Esperion Therapeutics, Inc. | $7.61 | 08/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1129448088 | CMS |
| Novartis Pharmaceuticals Corporation | $22.90 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086961256 | CMS |
| Lexicon Pharmaceuticals, Inc. | $4.71 | 08/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1081702729 | CMS |
| Esperion Therapeutics, Inc. | $11.84 | 08/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1129448086 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.93 | 08/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101500849 | CMS |
| ShockWave Medical, Inc | $24.26 | 08/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152999826 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $22.68 | 08/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117893687 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.99 | 08/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110534250 | CMS |
| Esperion Therapeutics, Inc. | $16.75 | 07/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1129448084 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.66 | 07/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101500834 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.75 | 07/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110546383 | CMS |
| MEDICOMP INC | $19.18 | 07/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1067448444 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.44 | 07/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110531399 | CMS |
| E.R. Squibb & Sons, L.L.C. | $25.80 | 07/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101500827 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.16 | 07/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101500830 | CMS |
| Novartis Pharmaceuticals Corporation | $15.03 | 07/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086961250 | CMS |
| Novartis Pharmaceuticals Corporation | $1.12 | 07/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086961252 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.13 | 07/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117893671 | CMS |
| Lexicon Pharmaceuticals, Inc. | $3.28 | 07/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1081702727 | CMS |
| ShockWave Medical, Inc | $20.96 | 07/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152988819 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.21 | 07/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101500819 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.28 | 07/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101500823 | CMS |
| Novartis Pharmaceuticals Corporation | $27.31 | 06/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086961272 | CMS |
| CVRx, Inc. | $26.16 | 06/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133854855 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.93 | 06/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101500808 | CMS |
| Esperion Therapeutics, Inc. | $13.77 | 06/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1129448082 | CMS |
| Medtronic, Inc. | $86.45 | 06/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247143494 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.15 | 06/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101500801 | CMS |
| E.R. Squibb & Sons, L.L.C. | $20.59 | 06/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101500805 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.03 | 06/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117893661 | CMS |
| Medtronic, Inc. | $56.80 | 06/15/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247143520 | CMS |
| Medtronic, Inc. | $378.00 | 06/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247143518 | CMS |
| PFIZER INC. | $34.97 | 06/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131667566 | CMS |
| Impulse Dynamics (USA) Inc. | $19.48 | 06/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100401872 | CMS |
| Novo Nordisk Inc | $13.89 | 06/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097155111 | CMS |
| Kiniksa Pharmaceuticals International, plc | $21.73 | 06/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154881137 | CMS |
| Kiniksa Pharmaceuticals International, plc | $3.67 | 06/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155169564 | CMS |
| CVRx, Inc. | $17.50 | 06/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133854853 | CMS |
| Actelion Pharmaceuticals US, Inc. | $124.99 | 06/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078908649 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.50 | 06/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110554636 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.15 | 06/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117893667 | CMS |
| Medtronic, Inc. | $22.83 | 06/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247143512 | CMS |
| Medtronic, Inc. | $40.85 | 06/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247143514 | CMS |
| Medtronic, Inc. | $18.82 | 06/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247143516 | CMS |
| Medtronic, Inc. | $68.44 | 06/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247143500 | CMS |
| Medtronic, Inc. | $44.28 | 06/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247143502 | CMS |
| Medtronic, Inc. | $26.09 | 06/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1247143504 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,422,870.52 | 276 |
| PY2024 | Recipient | $39,797.00 | 2 |
| PY2024 | Principal investigator | $2,947,044.76 | 148 |
| PY2023 | Recipient | $857.97 | 2 |
| PY2023 | Principal investigator | $3,176,608.43 | 319 |
| PY2022 | Recipient | $5,774.00 | 3 |
| PY2022 | Principal investigator | $3,440,257.96 | 262 |
| PY2021 | Principal investigator | $1,745,181.81 | 311 |
| PY2020 | Recipient | $2,445.30 | 3 |
| PY2020 | Principal investigator | $1,734,293.59 | 133 |
| PY2019 | Recipient | $2,576.33 | 2 |
| PY2019 | Principal investigator | $1,805,576.75 | 170 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
276 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $506.25 | 12/31/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228733364 |
| Principal investigator 1 | Cleerly, Inc. | $791.70 | 12/30/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241149079 |
| Principal investigator 1 | PFIZER INC. | $3,577.77 | 12/30/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228745836 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.66 | 12/17/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781320 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 12/17/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781322 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $17.40 | 12/17/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781324 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 12/15/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220999011 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 12/15/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817452 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,028.00 | 12/15/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817456 |
| Principal investigator 1 | Cleerly, Inc. | $3,390.40 | 12/12/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241149127 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,136.00 | 12/12/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264695 |
| Principal investigator 1 | PFIZER INC. | $11,000.00 | 12/12/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228745199 |
| Principal investigator 1 | PFIZER INC. | $4,500.00 | 12/11/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228743739 |
| Principal investigator 1 | PFIZER INC. | $16,274.79 | 12/11/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228749805 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $7,250.00 | 12/10/2025 | Non-covered Recipient Entity Capital Area Research, LLC | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215520025 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,598.00 | 12/10/2025 | Non-covered Recipient Entity Capital Area Research, LLC | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215520030 |
| Principal investigator 1 | Cleerly, Inc. | $11,339.90 | 12/02/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241149108 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781302 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781304 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781306 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781308 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781310 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781312 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220781326 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 12/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220781328 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 12/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220781330 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 12/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220781332 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $42,689.30 | 11/26/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event | No dispute reported | 06/30/2026 | 1185537231 |
| Principal investigator 1 | PFIZER INC. | $18,966.09 | 11/26/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228728467 |
| Principal investigator 1 | PFIZER INC. | $6,211.35 | 11/25/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228714731 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/21/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228725226 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/21/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228731803 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/21/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228735244 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/21/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228735279 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/21/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228735420 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/21/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228735426 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/21/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228735632 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/21/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228735637 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/21/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228735718 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/21/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228738858 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,416.00 | 11/19/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264856 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,331.40 | 11/13/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817454 |
| Principal investigator 1 | PFIZER INC. | $180.80 | 11/12/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228723724 |
| Principal investigator 1 | PFIZER INC. | $265.20 | 11/12/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228723920 |
| Principal investigator 1 | Cleerly, Inc. | $1,043.90 | 11/07/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241149067 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,634.00 | 11/07/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264880 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35,336.00 | 11/06/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264669 |
| Principal investigator 1 | Janssen Research & Development, LLC | $30,912.00 | 11/06/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264864 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,157.45 | 11/05/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185537237 |
| Principal investigator 1 | Cleerly, Inc. | $29,307.20 | 11/05/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241149095 |
| Principal investigator 1 | PFIZER INC. | $13,749.87 | 11/04/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228719937 |
| Principal investigator 1 | Janssen Research & Development, LLC | $480.00 | 11/03/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264733 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $27,324.64 | 11/03/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190303835 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781290 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781292 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781294 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781296 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781298 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781300 |
| Principal investigator 1 | PFIZER INC. | $16,237.80 | 10/30/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228742258 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 10/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781314 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 10/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781316 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.44 | 10/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781318 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 10/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220781334 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 10/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220781336 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,986.00 | 10/27/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175370152 |
| Principal investigator 1 | PFIZER INC. | $8,754.75 | 10/17/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228741945 |
| Principal investigator 1 | Cleerly, Inc. | $12,899.90 | 10/08/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241149056 |
| Principal investigator 1 | Cleerly, Inc. | $1,571.70 | 10/07/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241149063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781278 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781280 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781282 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781284 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781286 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781288 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 09/24/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781276 |
| Principal investigator 1 | PFIZER INC. | $17,986.40 | 09/24/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228769007 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,727.00 | 09/19/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264842 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,489.80 | 09/18/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817450 |
| Principal investigator 1 | Janssen Research & Development, LLC | $66,600.00 | 09/17/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264722 |
| Principal investigator 1 | PFIZER INC. | $6,977.62 | 09/09/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228757459 |
| Principal investigator 1 | Cleerly, Inc. | $1,680.90 | 09/05/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241149011 |
| Principal investigator 1 | Cleerly, Inc. | $25,543.70 | 09/05/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241149041 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 09/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781234 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781246 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781248 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781250 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781254 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781270 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,740.00 | 09/01/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264686 |
| Principal investigator 1 | PFIZER INC. | $22,449.17 | 08/26/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228768291 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,773.00 | 08/25/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264760 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,977.00 | 08/14/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264599 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,589.00 | 08/14/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264677 |
| Principal investigator 1 | PFIZER INC. | $3,412.80 | 08/11/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228714811 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,800.20 | 08/06/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817448 |
| Principal investigator 1 | PFIZER INC. | $36,669.46 | 08/05/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228768175 |
| Principal investigator 1 | Cleerly, Inc. | $18,870.80 | 08/04/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241149029 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781236 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781238 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781240 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781242 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781244 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781268 |
| Principal investigator 1 | Cleerly, Inc. | $1,695.20 | 07/31/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241148988 |
| Principal investigator 1 | Cleerly, Inc. | $2,507.70 | 07/31/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241148996 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $34,155.80 | 07/30/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) | No dispute reported | 06/30/2026 | 1190302273 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $474.50 | 07/28/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781272 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $17.40 | 07/28/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781274 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,911.00 | 07/28/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264804 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36,189.00 | 07/28/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264849 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,358.00 | 07/23/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264728 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,575.15 | 07/16/2025 | Non-covered Recipient Entity Capital Area Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215520004 |
| Principal investigator 1 | PFIZER INC. | $32,870.62 | 07/15/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228787175 |
| Principal investigator 1 | PFIZER INC. | $916.38 | 07/10/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228784118 |
| Principal investigator 1 | Cleerly, Inc. | $18,107.70 | 07/08/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241148950 |
| Principal investigator 1 | PFIZER INC. | $331.89 | 07/07/2025 | Non-covered Recipient Entity Capital Area Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228714729 |
| Principal investigator 1 | PFIZER INC. | $283.13 | 07/07/2025 | Non-covered Recipient Entity Capital Area Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228714733 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781256 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781258 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781260 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781262 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781264 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781266 |
| Principal investigator 1 | Cleerly, Inc. | $2,705.30 | 06/27/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241148968 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,480.80 | 06/26/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817446 |
| Principal investigator 1 | PFIZER INC. | $41,169.88 | 06/26/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228776661 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 06/24/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781230 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 06/24/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781232 |
| Principal investigator 1 | Cleerly, Inc. | $1,736.80 | 06/23/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241148910 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,277.00 | 06/23/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264832 |
| Principal investigator 1 | Amgen Inc. | $103,541.97 | 06/22/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246639907 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,895.00 | 06/20/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264637 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,158.00 | 06/20/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264766 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,680.00 | 06/20/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264794 |
| Principal investigator 1 | Cleerly, Inc. | $21,171.80 | 06/02/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241148937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781208 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781210 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781212 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781214 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781216 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781218 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781220 |
| Principal investigator 1 | PFIZER INC. | $9,880.17 | 05/31/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228772897 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,705.00 | 05/28/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264752 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 05/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781226 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 05/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781228 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,100.00 | 05/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817444 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,351.00 | 05/23/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175370162 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,141.00 | 05/21/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264612 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,568.00 | 05/20/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264630 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,675.00 | 05/20/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264789 |
| Principal investigator 1 | PFIZER INC. | $1,832.76 | 05/20/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228782578 |
| Principal investigator 1 | PFIZER INC. | $50,607.40 | 05/14/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228764249 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,706.50 | 05/09/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817442 |
| Principal investigator 1 | Cleerly, Inc. | $27,952.60 | 05/06/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241148924 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,600.00 | 05/06/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264782 |
| Principal investigator 1 | PFIZER INC. | $24,637.30 | 05/06/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228771836 |
| Principal investigator 1 | PFIZER INC. | $916.38 | 05/06/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228773295 |
| Principal investigator 1 | PFIZER INC. | $14,761.30 | 05/03/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228763608 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781196 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781198 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781200 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781202 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781204 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781206 |
| Principal investigator 1 | PFIZER INC. | $96,000.00 | 04/30/2025 | Non-covered Recipient Entity Capital Area Research LLC | A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE | No dispute reported | 06/30/2026 | 1228780564 |
| Principal investigator 1 | Cleerly, Inc. | $4,664.40 | 04/25/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241148891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 04/23/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781222 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 04/23/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781224 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,013.00 | 04/23/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264811 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $717.76 | 04/18/2025 | Non-covered Recipient Entity Capital Area Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215519938 |
| Principal investigator 1 | PFIZER INC. | $31,017.28 | 04/18/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228795756 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,071.00 | 04/17/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264647 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,460.00 | 04/17/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264714 |
| Principal investigator 1 | PFIZER INC. | $8,247.42 | 04/16/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228796518 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,019.80 | 04/11/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817440 |
| Principal investigator 1 | PFIZER INC. | $3,665.52 | 04/10/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228793809 |
| Principal investigator 1 | Cleerly, Inc. | $17,888.00 | 04/07/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241148870 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781184 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781186 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781188 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781190 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781192 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781194 |
| Principal investigator 1 | Novo Nordisk AS | $9,850.00 | 03/31/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | NN9535-4533 | No dispute reported | 06/30/2026 | 1213727809 |
| Principal investigator 1 | Novo Nordisk AS | $4,540.00 | 03/31/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | NN9535-4533 | No dispute reported | 06/30/2026 | 1213824692 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 03/25/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781174 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 03/25/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781176 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 03/25/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781178 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.52 | 03/25/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781180 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,062.00 | 03/25/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264706 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,320.00 | 03/25/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264743 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30,830.40 | 03/24/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817438 |
| Principal investigator 1 | PFIZER INC. | $43,020.65 | 03/22/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228779425 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,365.00 | 03/21/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264899 |
| Principal investigator 1 | Eli Lilly and Company | $58.67 | 03/18/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187880627 |
| Principal investigator 1 | Cleerly, Inc. | $3,554.20 | 03/11/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241148850 |
| Principal investigator 1 | Cleerly, Inc. | $13,410.80 | 03/10/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241148858 |
| Principal investigator 1 | PFIZER INC. | $2,749.14 | 03/04/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228720401 |
| Principal investigator 1 | PFIZER INC. | $1,578.76 | 03/04/2025 | Non-covered Recipient Entity Capital Area Research LLC | A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE | No dispute reported | 06/30/2026 | 1228781281 |
| Principal investigator 1 | PFIZER INC. | $1,854.02 | 03/04/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228782138 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781142 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781144 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781146 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781148 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781150 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781152 |
| Principal investigator 1 | PFIZER INC. | $2,454.39 | 02/28/2025 | Non-covered Recipient Entity Capital Area Research LLC | A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE | No dispute reported | 06/30/2026 | 1228770744 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,912.00 | 02/27/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264819 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,416.00 | 02/27/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264825 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,457.00 | 02/27/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264871 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,250.00 | 02/27/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264908 |
| Principal investigator 1 | Amgen Inc. | $286,040.84 | 02/25/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | No dispute reported | 06/30/2026 | 1246639905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 02/25/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781170 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 02/25/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781172 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,063.00 | 02/19/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264606 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,787.00 | 02/19/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264774 |
| Principal investigator 1 | Novo Nordisk AS | $6,094.06 | 02/19/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | NN9535-4533 | No dispute reported | 06/30/2026 | 1213759963 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,022.00 | 02/18/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264653 |
| Principal investigator 1 | PFIZER INC. | $15,171.58 | 02/14/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY | No dispute reported | 06/30/2026 | 1228750302 |
| Principal investigator 1 | Novo Nordisk AS | $750.00 | 02/12/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | NN9535-4533 | No dispute reported | 06/30/2026 | 1213805188 |
| Principal investigator 1 | Eli Lilly and Company | $11,500.00 | 02/10/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A STUDY OF LY3819469 IN PARTICIPANTS WITH ELEVATED LIPOPROTEIN(A) [LP(A)] | No dispute reported | 06/30/2026 | 1187876525 |
| Principal investigator 1 | Cleerly, Inc. | $8,450.00 | 02/07/2025 | Non-covered Recipient Entity Capital Area Research, LLC | TRANSFORM | No dispute reported | 06/30/2026 | 1241148845 |
| Principal investigator 1 | PFIZER INC. | $4,702.43 | 02/05/2025 | Non-covered Recipient Entity Capital Area Research LLC | A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE | No dispute reported | 06/30/2026 | 1228723482 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781130 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781132 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781134 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781136 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781138 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781140 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $27,750.52 | 01/29/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185537233 |
| Principal investigator 1 | Eli Lilly and Company | $4,522.89 | 01/29/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187880621 |
| Principal investigator 1 | Amgen Inc. | $24,487.77 | 01/27/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246639901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 01/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781154 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 01/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781156 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $474.50 | 01/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781158 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $663.30 | 01/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781160 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.55 | 01/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781162 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.45 | 01/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781164 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.66 | 01/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781166 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22.08 | 01/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781168 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,207.00 | 01/27/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817436 |
| Principal investigator 1 | Eli Lilly and Company | $263.75 | 01/27/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187877257 |
| Principal investigator 1 | Eli Lilly and Company | $4,348.32 | 01/27/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187880625 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500.00 | 01/23/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817434 |
| Principal investigator 1 | Janssen Research & Development, LLC | $30,099.00 | 01/22/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175264888 |
| Principal investigator 1 | Eli Lilly and Company | $72,017.00 | 01/21/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187877959 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,969.00 | 01/21/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264623 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,475.00 | 01/21/2025 | Non-covered Recipient Entity Cptal Area Rsrch Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175264661 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $31,378.29 | 01/21/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190302271 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,887.80 | 01/17/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817430 |
| Principal investigator 1 | PFIZER INC. | $1,115.10 | 01/14/2025 | Non-covered Recipient Entity Capital Area Research LLC | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228799773 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $435,007.00 | 01/13/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190311151 |
| Principal investigator 1 | PFIZER INC. | $818.13 | 01/10/2025 | Non-covered Recipient Entity Capital Area Research LLC | A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE | No dispute reported | 06/30/2026 | 1228798324 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $5,984.33 | 01/08/2025 | Non-covered Recipient Entity Capital Area Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215519844 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,459.05 | 01/08/2025 | Non-covered Recipient Entity Capital Area Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215519848 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,068.58 | 01/08/2025 | Non-covered Recipient Entity Capital Area Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215519852 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,627.32 | 01/08/2025 | Non-covered Recipient Entity Capital Area Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215519857 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,624.92 | 01/08/2025 | Non-covered Recipient Entity Capital Area Research, LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215519861 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 01/07/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817432 |
| Principal investigator 1 | Eli Lilly and Company | $127,676.00 | 01/07/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187876477 |
| Principal investigator 1 | Eli Lilly and Company | $203,338.00 | 01/07/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187876527 |
| Principal investigator 1 | Eli Lilly and Company | $139,483.00 | 01/07/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187878343 |
| Principal investigator 1 | Eli Lilly and Company | $71,130.00 | 01/07/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187880623 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $46,343.65 | 01/03/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function | No dispute reported | 06/30/2026 | 1185537229 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $16,200.00 | 01/03/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185537235 |
| Principal investigator 1 | Amgen Inc. | $85,910.60 | 01/02/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke | No dispute reported | 06/30/2026 | 1246639903 |
| Principal investigator 1 | Eli Lilly and Company | $4,362.90 | 01/02/2025 | Non-covered Recipient Entity CAPITAL AREA RESEARCH LLC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187880629 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781120 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781122 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781124 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781126 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781128 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Capital Area Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220781182 |